Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Rule 8.3-Angle Plc

12 May 2008 13:20

RNS Number : 2093U
Kaupthing Bank hf
12 May 2008
 
FORM 8.3
DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE
(Rule 8.3 of the Takeover Code)
 
 
1. KEY INFORMATION
 
Name of person dealing (Note 1)
Kaupthing Bank hf
Company dealt in
Angle Plc
Class of relevant security to which the dealings being disclosed relate(Note 2)
Ordinary Shares
Date of dealing
09 May 2008
 
 
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
 
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
 
 
 
Long
Short
 
 
Number (%)
Number (%)
(1) Relevant securities
 
 
9,418 (0.03%)
(2) Derivatives (other than options)
 
1,017,125 (3.75 %)
 
1,017,125 (3.75 %)
 
(3) Options and agreements to purchase/sell
 
 
 
Total
 
1,017,707 (3.75 %)
 
1,026,543 (3.78 %)
 
 
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
 
Class of relevant security:
 
Long
Short
 
 
Number (%)
Number (%)
(1) Relevant securities
 
 
 
(2) Derivatives (other than options)
 
 
 
(3) Options and agreements to purchase/sell
 
 
 
Total
 
 
 
 
(c) Rights to subscribe (Note 3)
 
Class of relevant security:
 
Details
 
 
 
 
 
3. DEALINGS (Note 4)
 
(a) Purchases and sales 
 
Purchase/sale
 
Number of securities
Price per unit (Note 5)
Sell
10,000
39.50p
 
 
 
 (b) Derivatives transactions (other than options)
 
Product name,
e.g. CFD
Long/short (Note 6)
Number of securities (Note 7)
Price per unit (Note 5)
 
 
 
 
 
 
 
 
 
 
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
 
Product name,
e.g. call option
 
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise
price
Type, e.g. American, European etc.
Expiry
date
Option money
paid/received per unit (Note 5)
 
 
 
 
 
 
 
 
 
 
 
 
(ii) Exercising
 
Product name, e.g. call option
Number of securities
Exercise price per unit (Note 5)
 
 
 
 
 
 
(d) Other dealings (including new securities) (Note 4)
 
Nature of transaction (Note 8)
 
Details
Price per unit (if applicable)(Note 5)
 
 
 
 
 
 
4. OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. 
No voting rights on CFD holdings
 
 
 
Is a Supplemental Form 8 attached? (Note 9) NO
 
 
Date of disclosure
12 May 2008
Contact name
Richard Easton
Telephone number
0203 205 6620
If a connected EFM, name of offeree/offeror with which connected
 
If a connected EFM, state nature of connection (Note 10)
 
 
 
Notes
 
The Notes on Form 8.3 can be viewed on the Takeover Panel’s website at www.thetakeoverpanel.org.uk
 
 
This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETXLLFFVEBFBBD
Date   Source Headline
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.